Skip to content
Gene2Rx home

Try

Loading…

Search couldn't load. Check your connection and try again, or use the medication lookup.

No pages match .

The medication lookup checks any medication by name, including ones without their own page.

Get my report

Abacavir

Nucleoside Reverse Transcriptase Inhibitor (NRTI)

Abacavir (Ziagen, and in combination products such as Epzicom and Trizivir) is an HIV medicine. People who carry the HLA-B*57:01 allele have a much higher risk of a serious, sometimes fatal hypersensitivity reaction to it. CPIC recommends that carriers not receive abacavir [1], and the FDA label says everyone should be tested for HLA-B*57:01 before starting or restarting it [2]. Gene2Rx does not test HLA genes, so a Gene2Rx report cannot tell you whether you carry HLA-B*57:01.

At a glance
Brand namesZiagen; combinations including Epzicom (with lamivudine) and Trizivir (with lamivudine and zidovudine)
Used forHIV-1 infection, with other antiretroviral medicines
GenesHLA-B (the HLA-B*57:01 allele)
GuidanceCPIC guideline (2012, confirmed 2014) [1]; FDA label (boxed warning, sections 2.1, 4 and 5.1) [2]
Gene2Rx coverageNot tested. Gene2Rx does not call HLA genes from any uploaded data.

How abacavir works

Abacavir is a nucleoside reverse transcriptase inhibitor. It blocks the viral enzyme that copies HIV's RNA genome into DNA, which the virus needs before it can insert itself into a host cell's genome. It is always used with other antiretroviral drugs [1]. The usual adult dose is 600 mg a day, taken as 300 mg twice daily or 600 mg once daily [2].

Abacavir is not broken down to a significant extent by the cytochrome P450 enzymes that most drug-gene results concern. Alcohol dehydrogenase and glucuronidation clear it, and its plasma half-life after a single dose is about 1.5 hours [2]. HLA-B status does not change abacavir levels or how well it works; it changes only the chance of a hypersensitivity reaction [1].

How HLA-B*57:01 affects abacavir

HLA-B is one of the genes that make the molecules cells use to show protein fragments to the immune system, so that infected cells can be recognized. HLA genes are extremely variable: more than 1,500 HLA-B alleles were known when CPIC wrote its guideline. Some drugs can provoke an immune reaction through particular HLA molecules, and abacavir hypersensitivity is strongly linked to one allele, HLA-B*57:01 [1].

Without genetic screening, about 5 to 8% of people starting abacavir had a hypersensitivity reaction, usually in the first 6 weeks [1]. In the label's pooled clinical trials without screening, 206 of 2,670 patients (8%) had a reaction, and the rate fell to 1% when carriers of HLA-B*57:01 were excluded; the median time to onset was 9 days. Reactions can involve several organs and have been fatal [2]. CPIC describes the typical picture as two or more of fever, rash, stomach symptoms (nausea, vomiting, abdominal pain), fatigue, cough and shortness of breath, worsening if the drug is continued. After a reaction, restarting abacavir can cause an immediate, life-threatening reaction [1].

The evidence is unusually strong. In the PREDICT-1 randomized trial, no immunologically confirmed reactions occurred in screened patients who tested negative, compared with 2.7% of 842 unscreened patients. About half of HLA-B*57:01 carriers given abacavir have an immunologically confirmed reaction, so being positive does not make a reaction certain. The allele frequency varies by ancestry: about 6 to 7% in European populations, with up to 20% of people being carriers in some Southwest Asian populations, and it is lowest in African and Asian populations and absent in some, including Japanese [1].

What the guidelines recommend

CPIC published its HLA-B and abacavir guideline in 2012 and reviewed it in 2014, finding no new evidence that would change it [1] [3]. CPIC recommends testing everyone who has not taken abacavir before, in line with the FDA, the US Department of Health and Human Services and the European Medicines Agency. The 2014 update applies the same advice to children [3]. The FDA label goes further: test everyone before starting or restarting abacavir unless a previous HLA-B*57:01 result is documented [2].

HLA-B*57:01 results and abacavir
ResultWhat it meansGuideline recommendation
HLA-B*57:01 negativeNo copy of the allele. Low risk of hypersensitivity, though reactions still occur rarely.CPIC (strong): use abacavir per standard dosing.
HLA-B*57:01 positive (one or two copies)Much higher risk of hypersensitivity.CPIC (strong): abacavir is not recommended, except in exceptional circumstances where benefit outweighs risk. FDA label: contraindicated [2].

There is no intermediate result: one copy is enough to count as positive [1]. The FDA's Table of Pharmacogenetic Associations says the same in one line: do not use abacavir in people positive for HLA-B*57:01 [4].

Getting tested

The HLA-B*57:01 test is a clinical laboratory test ordered by your HIV clinician, usually before an abacavir-containing regimen is chosen. CPIC prefers a test that looks specifically for HLA-B*57:01, because broader HLA typing adds nothing useful for this decision, and the result is reported simply as positive or negative [1]. Ask whether the test has been done, and keep a copy of the result: the label allows a documented earlier result to stand in for repeat testing [2].

A negative test does not remove the need for care. The label says abacavir must be stopped immediately if a hypersensitivity reaction is suspected, whatever the HLA-B*57:01 result, and never restarted after a reaction [2]. Do not stop or change HIV medicines on your own; talk to your clinician.

What a Gene2Rx report cannot tell you

Gene2Rx does not call HLA genes, from consumer DNA tests or from whole-genome sequencing. A Gene2Rx report therefore contains no HLA-B*57:01 result and gives no abacavir recommendation, and nothing in it, including any other gene result, can be read as clearing you for abacavir. The guideline answer requires the clinical HLA-B*57:01 test described above.

If you take abacavir, other parts of a Gene2Rx report may still matter for your other medicines, but not for this one.

Common questions

Can my 23andMe or AncestryDNA data tell me if I carry HLA-B*57:01?

Not through Gene2Rx, which does not interpret HLA genes. For a decision about abacavir, CPIC and the FDA label rely on a clinical HLA-B*57:01 test [1] [2].

I have taken abacavir before without problems. Do I need the test?

The label says to test before restarting abacavir unless a result is already documented [2]. CPIC notes there is some debate about people who previously tolerated it, and found no data showing that carriers with earlier safe exposure have zero risk on re-exposure [1].

Does HLA-B*57:01 matter for other drugs?

CPIC notes that HLA-B*57:01 has also been linked to liver injury from the antibiotic flucloxacillin, but that reaction is rare and routine screening is not done for it [1].

Sources and further reading

Disclaimer: This document is for informational purposes only and is not a substitute for medical advice. Clinical decisions should be made by a qualified healthcare professional.

Interested in learning more about how your genetics may affect your response to medication? Get started with Gene2Rx today.

I'm Interested